Conventional DAPT
Phase 3Small molecule
Conventional DAPT is one of 54 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
117 competitors in Coronary Artery Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Brilinta
AstraZenecaApproved
Crestor
AstraZenecaApproved
Farxiga
AstraZenecaApproved
Niacor
AbbVieApproved
Ozempic
Novo NordiskApproved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Glucophage
EMD SeronoApproved
Aggrastat
MMedicure
Approved
Cardizem
BBausch Health Americas, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Conventional DAPT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- ZZunyi Medical College